Commercialization, Specialty Drug, Specialty HUBs
Idorsia Ltd. Strengthens Commercialization Collaboration with Syneos Health
26
Jan
Jan
Idorsia Ltd. and Syneos Health® announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada